Baker Tilly Wealth Management LLC Sells 362 Shares of Zoetis Inc. $ZTS

Baker Tilly Wealth Management LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 16.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,801 shares of the company’s stock after selling 362 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Zoetis were worth $281,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Brighton Jones LLC boosted its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. State of Wyoming boosted its holdings in Zoetis by 1,074.0% in the 4th quarter. State of Wyoming now owns 2,125 shares of the company’s stock valued at $346,000 after purchasing an additional 1,944 shares during the period. Tidal Investments LLC boosted its holdings in Zoetis by 22.7% in the 4th quarter. Tidal Investments LLC now owns 18,668 shares of the company’s stock valued at $3,042,000 after purchasing an additional 3,458 shares during the period. Two Sigma Investments LP raised its position in shares of Zoetis by 632.7% during the 4th quarter. Two Sigma Investments LP now owns 138,239 shares of the company’s stock valued at $22,523,000 after buying an additional 119,372 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Zoetis by 18.4% during the 4th quarter. Two Sigma Advisers LP now owns 39,900 shares of the company’s stock valued at $6,501,000 after buying an additional 6,200 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Stock Performance

Zoetis stock opened at $147.16 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $65.22 billion, a PE ratio of 25.33, a P/E/G ratio of 2.36 and a beta of 0.89. The firm has a fifty day simple moving average of $151.43 and a two-hundred day simple moving average of $156.76. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.